Logo

IntegraGen and Aventis Ink Schizophrenia Research Collaboration

Jan 30, 2004

NEW YORK, Jan. 30 (GenomeWeb News) - IntegraGen and Aventis will jointly search for genes associated with schizophrenia, the companies said today.

 

Aventis will use IntegraGen's Genome Hybrid Identity Profiling gene mapping technology to perform genome-wide linkage analysis on DNA samples from schizophrenia patients, collected by Aventis' Human Genetics Center in Evry, France.

 

This is IntegraGen's first commercial deal for the application of GenomeHIP, according to the company, which is located in suburban Paris.

 

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.